scholarly journals Respiratory Infections and Activity of Anti-Flu Vaccine in Patients with Lymphoma and Multiple Myeloma

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4617-4617
Author(s):  
Noa Lavi ◽  
Emilia Hardak ◽  
Ilana Oren ◽  
Irit Avivi
Keyword(s):  
Multiple Myeloma ◽  
Cancer Therapy ◽  
Respiratory Infection ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Viral Pathogen ◽  
Flu Vaccination ◽  
Anti Cancer ◽  
Flu Vaccine ◽  
Tract Infections

Abstract Introduction: The significance of viral respiratory infections (VRI) and efficacy of anti-flu vaccine in patients (pts) with lymphoproliferative malignancies (LPM) have not been fully elucidated. The current large comprehensive study was designed to evaluate the incidence of respiratory infections in LPM pts, define clinical significance of VRI and assess the impact of anti-flu vaccine on RI prevention in this population. Methods: All consecutive pts, diagnosed either with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), followed at the Rambam Hematology Outpatient Unit between 01/2011 and 03/2012 (during or after anti-cancer therapy or untreated) were evaluated. Data regarding anti-lymphoma/MM therapy used, respiratory infections occurring during the study period, tests performed to assess these infections (focusing on viral ones), administration of anti-flu vaccine and infection-related outcome were recorded. Samples of nasopharyngeal aspirate (NPA) or bronchoalveolar lavage (BAL) were evaluated for VRI pathogens using both immunofluorescence and polymerase chain reaction (PCR) methods. Results: Five hundred and sixty two respiratory infection episodes were reported in 369 pts. In 224 (40%) episodes, VRI investigation was performed using either NPA (n=180) or BAL (n=44) samples. The decision regarding the sample source was taken based on the respiratory infection severity. The cohort screened for VRI included a larger proportion of pts receiving anti-cancer therapy during the study period than the non-screened cohort (70% vs 30%, respectively, p<0.01). The number of respiratory episodes requiring hospitalization for their respiratory infection was higher in the former cohort (54% vs 18%). One hundred fifty two screened episodes were community-acquired (50 required hospitalization) and 72 were hospital-acquired. Fever was the most common clinical symptom in screened episodes (n=111, 50%), followed by cough (n=91, 41%), dyspnea (n= 87, 39%), runny nose (n=47, 21%), respiratory distress (n=45, 20%): with decreased O2 saturation (n=35, 16%) and mechanical ventilation (n=10, 4%). In 12% and 23% of episodes, respectively, neutropenia and significant hypogammaglobinemia (IgG <500 mg/dl) were revealed. VRI were identified in 66/224 episodes (29%), 59 episodes were viral infections and 7 - co-infections (viral with another pathogen). Sixty viral episodes were diagnosed in pts with upper respiratory tract infections and 6 in pts with pneumonia. Cough, abnormal lung physical findings and hypogammaglobinemia were statistically more frequent in pts with viral infections vs those with other respiratory infections. Viral infections were treated according to pathogens recognized. Tamiflu was prescribed for influenza infections and ribavirin was given for part of the respiratory syncytial virus (RSV) infections. Supportive treatment only was given for parainfluensa and metapneumovirus infections. Twelve episodes of VRI, developed outside of hospital, required hospitalization (5%) and 2 of these episodes resulted in death. The most frequent viral infection was Influenza A (22 cases), followed by RSV (14 cases), parainfluenza and metapneumovirus (11 cases each). Less frequent viral pathogens were Influenza B (6 cases), and adenovirus (2 cases). Seven cases (10%) were accompanied with a secondary bacterial or fungal infection. Notably, 3 of the 10 pts diagnosed with RSV infection had a concurrent Aspergillus infection. Data regarding anti-flu vaccination were available in 701 pts; 431 pts (61%) were vaccinated. In a univariate analysis, anti-flu vaccination was found to have no impact on the respiratory infection frequency (51% vs 48.9%, p=0.752). Among pts with VRI, 49% did and 45% did not previously receive anti-flu vaccination (p=0.95). This vaccination had no effect on the VRI incidence in the investigated episodes. Conclusions: VRI, although frequent, are usually associated with a good outcome in LPM pts. Presence of cough and abnormal pulmonary examination were found to predict a positive screen for a viral pathogen. Influenza and RSV, both potentially treatable with Tamiflu and ribavirin, respectively, were responsible for 55% of VRI episodes, justifying a wider use of viral screening in LPM pts. Anti-flu vaccination has not proved its efficacy either in preventing viral infections or in reducing the entire incidence of respiratory infections in these pts. Disclosures No relevant conflicts of interest to declare.

scholarly journals Potential Neurocognitive Symptoms Due to Respiratory Syncytial Virus Infection

Pathogens ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 47
Author(s):  
Catalina A. Andrade ◽  
Alexis M. Kalergis ◽  
Karen Bohmwald
Keyword(s):  
Respiratory Syncytial Virus ◽  
Viral Infections ◽  
Respiratory Infections ◽  
The Elderly ◽  
Cell Types ◽  
Potential Effect ◽  
Viral Agent ◽  
Pulmonary Manifestations ◽  
Syncytial Virus ◽  
Tract Infections

Respiratory infections are among the major public health burdens, especially during winter. Along these lines, the human respiratory syncytial virus (hRSV) is the principal viral agent causing acute lower respiratory tract infections leading to hospitalization. The pulmonary manifestations due to hRSV infection are bronchiolitis and pneumonia, where the population most affected are infants and the elderly. However, recent evidence suggests that hRSV infection can impact the mother and fetus during pregnancy. Studies have indicated that hRSV can infect different cell types from the placenta and even cross the placenta barrier and infect the fetus. In addition, it is known that infections during the gestational period can lead to severe consequences for the development of the fetus due not only to a direct viral infection but also because of maternal immune activation (MIA). Furthermore, it has been described that the development of the central nervous system (CNS) of the fetus can be affected by the inflammatory environment of the uterus caused by viral infections. Increasing evidence supports the notion that hRSV could invade the CNS and infect nervous cells, such as microglia, neurons, and astrocytes, promoting neuroinflammation. Moreover, it has been described that the hRSV infection can provoke neurological manifestations, including cognitive impairment and behavioral alterations. Here, we will review the potential effect of hRSV in brain development and the potential long-term neurological sequelae.

scholarly journals Clinical-epidemiological peculiarities of acute respiratory infections in children from 3 to 12 years and evaluation of effectiveness of antivirus therapy

2019 ◽  
Vol 11 (3) ◽  
pp. 38-45
Author(s):  
S. A. Khmilevskaya ◽  
N. I. Zryachkin ◽  
V. E. Mikhailova
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Molecular Genetic ◽  
Respiratory Viruses ◽  
Acute Respiratory Infections ◽  
Age Group ◽  
Leading Role ◽  
Respiratory Viral Infections ◽  
Acute Respiratory Viral Infection ◽  
Tract Infections

The aim: to study the etiological structure of acute respiratory infections in children aged 3 to 12 hospitalized in the early stages of the disease in the department of respiratory infections of the children’s hospital, and to reveal the features of their clinical course and the timing of DNA / RNA elimination of respiratory viruses from nasal secretions, depending on the method of therapy. Materials and methods: 100 children with acute respiratory infections aged 3 to 12 years were monitored. The nasal secrets on the DNA / RNA of respiratory viruses were studied by PCR. Depending on the method of therapy, patients were divided into 2 groups: patients of group 1 (comparison) received basic treatment (without the use of antiviral drugs), in patients of the 2nd group (main), along with basal therapy, the drug was used umifenovir in a 5-day course at the ageappropriate dosage. Results: In the etiologic structure of ARVI in children from 3 to 12 years, the leading place was taken by rhinovirus, influenza and metapneumovirus infections (isolated – 18%, 19% and 20% respectively, in the form of a mixed infection – 11%). The main syndromic diagnosis at the height of the disease was rhinopharyngitis. Complications were observed in 42% of cases, as often as possible with flu – 53% of cases. Features of metapneumovirus infection in children of this age group were: predominance of non-severe forms of the disease in the form of acute fever with symptoms of rhinopharyngitis, as well as a small incidence of lower respiratory tract infections. The use of the drug umiphenovir in children with acute respiratory viral infections of various etiologies contributed to significantly faster elimination of viral DNA / RNA from the nasal secretion, which was accompanied by a ecrease in the duration of the main clinical and hematological symptoms of the disease, a decrease in the incidence of complications, and reduced the duration of stay in hospital. Conclusion: application of modern molecular genetic methods of diagnostics made it possible to identify the leading role of influenza, metapneumovirus and rhinovirus infections in the etiology of acute respiratory viral infection in patients aged 3 to 12 years, and to determine a number of clinical features characteristic of this age group. The results of the study testify to the effectiveness of umiphenovir in the treatment of children with acute respiratory viral infections of various etiologies and allow us to recommend this drug as an effective and safe etiotropic agent.

Antibiotic therapy of acute upper respiratory tract infections and otitis media in adults

2018 ◽  
Vol 7 (1) ◽  
pp. 1-7
Author(s):  
Aleksandra Paź ◽  
Magdalena Arimowicz
Keyword(s):  
Respiratory Tract ◽  
Antibiotic Therapy ◽  
Respiratory Tract Infections ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Symptomatic Treatment ◽  
Upper Respiratory Tract Infections ◽  
Upper Respiratory Tract ◽  
Upper Respiratory ◽  
Tract Infections

An estimated 50% of antibiotic prescriptions may be unjustified in the outpatient setting. Viruses are responsible for most acute respiratory tract infections. The viral infections are often self-limiting and only symptomatic treatment remains effective. Bacteria are involved in a small percentage of infections etiology in this area. In the case of a justified or documented suspicion of a bacterial infection, antibiotic therapy may be indicated. Based on the Polish „Recommendations for the management of non-hospital respiratory infections 2016”, the indications, the rules of choice, the appropriate dosing schedules and the therapy duration, in the most frequent upper respiratory tract infections in adults, have been presented. Implementation of the presented recommendations regarding our Polish epidemiological situation, will significantly reduce the tendency to abuse antibiotics, and thus will limit the spread of drug-resistant microorganisms.

Parainfluenza type 3 outbreaks in Izmir children, Turkey

2007 ◽  
Vol 37 (4) ◽  
pp. 252-254
Author(s):  
Figen Gülen ◽  
Candan Cicek ◽  
Zafer Kurugol ◽  
Esen Demir ◽  
Dost Zeyrek ◽  
...  
Keyword(s):  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Lower Respiratory Tract Infections ◽  
Parainfluenza Viruses ◽  
Syncytial Virus ◽  
Aetiological Diagnosis ◽  
Tract Infections ◽  
Type 3

The present study was aimed to investigate characteristics of lower respiratory tract infections caused by parainfluenza type 3 viruses. Nasopharyngeal smears were taken from 178 patients with lower respiratory infections for the diagnosis of respiratory syncytial virus, adenovirus, influenza and parainfluenza viruses between December 2004 and April 2005. Parainfluenza type 3 was isolated from the viral specimens of 96 (53.9%) patients and it was noticeable that the parainfluenza type 3 outbreak occurs during winter. Obviously, improving the aetiological diagnosis of viral infections might avoid unnecessary therapy, antibiotics in particular, and would allow for preventive isolation of infected patients.

scholarly journals Risk factors associated with Acute Respiratory Infection (ARI) among children under 10-years in Rohingya refugee camp

2020 ◽  
pp. 32-35
Author(s):  
Shafiqua Nawrin Oishi ◽  
Nazmul Alam
Keyword(s):  
Risk Factors ◽  
Respiratory Infection ◽  
Acute Respiratory Infection ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Cross Sectional Study ◽  
Nasal Discharge ◽  
Cross Sectional ◽  
Factors Associated ◽  
Aged People

Acute respiratory infections are cause by bacterial, fungal or viral infections of the respiratory tract. Very young and older aged people are most vulnerable of these infections lead to difficulties from fever, cough, nasal discharge, sputum production, fatigue, wheezing, pain on swallowing, at times ear infections and meningitis. With huge number of Rohingya influx in Bangladesh, camps are overly crowded allowing many infectious diseases to transmit easily. Although there are researches that have been conducted in this area, there remains a huge gap of research in these camps where children being vulnerable are mostly suffering from respiratory disease such as Acute Respiratory Infection (ARI). This cross-sectional study investigated the risk factors associated with ARI among children less than 10 years in Rohingya refugee camps. After collecting information based on their demographic, anthropometric, history of respiratory problem, accommodation and nutritional status, it was found that about 21.6% of 259 children under this study had symptoms of ARI. Living in congested housing and with lack of nutritious food children were found negatively associated with ARI.

scholarly journals Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 3865-3865
Author(s):  
Taiga Nishihori ◽  
James E. Hoffman ◽  
Jonathan L. Kaufman ◽  
Anne Huff ◽  
Charlotte Snape ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cancer Therapy ◽  
Research Funding ◽  
Cell Kinetics ◽  
Publicly Traded ◽  
Myeloma Cells ◽  
Safety And Efficacy ◽  
Anti Cancer ◽  
Grade 3

Abstract Background: Outcomes remain poor for patients with relapsed and refractory multiple myeloma (RRMM) progressing on conventional therapy (proteasome inhibitors, IMiDs, anti-CD38 antibodies, BCMA targeting agents, corticosteroids). Lete-cel, an autologous T-cell therapy, targets NY-ESO-1/LAGE-1a+ tumors using a genetically modified, high-affinity T-cell receptor. NY-ESO-1 and LAGE-1a are immunogenic cancer/testis antigens frequently overexpressed in MM and are linked to poor clinical outcomes. Additionally, PD-1 expression, which may limit adaptive immune response, has been observed previously in RRMM patients following treatment with lete-cel (Stadtmauer et al. Blood Adv, 2019; 3: 2022-2034). This open-label, pilot study evaluated the safety and efficacy of lete-cel +/- pembrolizumab (pembro) in patients with RRMM. Study design and methods: Key eligibility criteria include: age ≥18 yr; HLA-A*02:01; A*02:05, and/or A*02:06; NY-ESO-1+ and/or LAGE-1a+; protocol-required prior regimens; specified washouts from prior therapy; no active/chronic/intercurrent illness. Following lymphodepletion (LD), patients received lete-cel (Arm 1) or lete-cel + pembro (Arm 2). Planned pembro dosing was 200 mg/dose Q3 weeks (wks) starting at Wk 3. Primary endpoint was safety and tolerability. Key efficacy endpoint was investigator-assessed overall response rate (ORR) by International Myeloma Working Group uniform response criteria for MM (2016); response was assessed Q3 wks from Wk 3 to Wk 24, then Q6 wks to Wk 72, then every 3 months (mo) to disease progression/death/withdrawal. NY-ESO-1/LAGE-1a expression was assessed by qRT-PCR on myeloma cells. Transduced cell kinetics were assessed by qPCR of transgene vector copies in DNA from peripheral blood mononuclear cells. Results: Six patients (all male; median age 63 yr) were enrolled; 3 per arm. All had prior systemic anti-cancer therapy; 3 patients had received ≥5 prior regimens. Five of 6 patients received systemic anti-cancer therapy between leukapheresis and LD. All received reduced LD due to age and, in some patients, renal impairment. Patients in each arm received similar numbers of transduced T cells. Each of the 3 patients in Arm 2 received a median of 3 pembro doses (range: 3-4 doses). Start of pembro dosing was delayed to Wk 6 in 2 patients due to ongoing toxicities. There were no Grade 5 AEs. Grade 3/4 T-cell related AEs were reported in 3 patients, and all patients had Grade 3/4 LD-related AEs. Hematopoietic cytopenias were the most common treatment-emergent and treatment-related Grade 3/4 AE, occurring in all patients. All cytopenias were reported to have resolved for 4 patients or to have improved to Grade 1 at final patient follow-up for 2 patients. Three patients had cytokine release syndrome (Arm 1: 1 patient, Grade 2; Arm 2: 2 patients; 1 Grade 1 and 1 Grade 2); all patients recovered. There was 1 event of graft vs host disease (GvHD skin; Grade 1) and, in a separate patient, 1 event of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) (Grade 1). Both events resolved. All patients had reduction in tumor burden. Arm 1 (lete-cel alone) had an ORR of 33.3% (1 CR, 2 SD) and median progression-free survival (PFS) of 2.79 mo, while Arm 2 (combination) had an ORR of 66.7% (1 VGPR, 1 PR, 1 SD) and median PFS of 2.78 mo. Time to response for all responders was 3 weeks. Pembro dosing for the 2 Arm 2 responders began at Wk 6. Duration of response in each responder was 2.1 mo. Overall survival data are not mature. Two of 3 responders exhibited clearance of antigen positive myeloma cells in the bone marrow for up to 6 weeks after lete-cel infusion. T cell kinetics trended toward higher peak expansion (Cmax) and area under the curve (AUC) over the first 28 days post-dose (AUC0-28d) in responders vs. non-responders. Serum cytokine profiles in relation to response and CRS will be discussed. Conclusions: A single lete-cel infusion was associated with antitumor activity in 6/6 heavily pretreated RRMM patients, including 1 CR, 1 VGPR, 1PR. Both responses in Arm 2 occurred prior to pembro initiation. The associated safety profile was manageable and consistent with that seen in other lete-cel studies. Responders showed a trend toward higher Cmax and AUC0-28d as compared to non-responders. The study was closed in November 2020 due to protracted enrollment. This study (208470; NCT03168438) was funded by GlaxoSmithKline. Submission support was provided by Fishawack Health. Disclosures Nishihori: Novartis: Research Funding; Karyopharm: Research Funding. Kaufman: Janssen: Honoraria; Heidelberg Pharma: Research Funding; Fortis Therapeutics: Research Funding; Tecnofarma SAS, AbbVie: Honoraria; Amgen: Research Funding; BMS: Consultancy, Research Funding; Incyte, celgene: Consultancy; Incyte, TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Genentech, AbbVie, Janssen: Consultancy, Research Funding; Novartis: Research Funding; Roche/Genetech, Tecnopharma: Consultancy, Honoraria; Sutro, Takeda: Research Funding. Huff: GSK: Current Employment, Current equity holder in publicly-traded company. Snape: Veramed: Current Employment. Jain: Butterfly Network: Current equity holder in publicly-traded company; Marker Therapeutics: Current equity holder in publicly-traded company; 23 and Me: Current equity holder in publicly-traded company; Sema4 Holdings: Current equity holder in publicly-traded company; GSK: Current Employment, Current equity holder in publicly-traded company. Kapoor: GSK: Current equity holder in publicly-traded company. Zajic: GSK: Current Employment, Current equity holder in publicly-traded company. Suchindran: GSK: Current Employment, Current equity holder in publicly-traded company. Chisamore: Merck & Co. Inc: Current Employment, Current equity holder in publicly-traded company. Rapoport: GSK: Other: Support received as site principal investigator for this study.

scholarly journals Seasonal Coronaviruses and Other Neglected Respiratory Viruses: A Global Perspective and a Local Snapshot

2021 ◽  
Vol 9 ◽  
Author(s):  
Sunčanica Ljubin-Sternak ◽  
Tomislav Meštrović ◽  
Ivana Lukšić ◽  
Maja Mijač ◽  
Jasmina Vraneš
Keyword(s):  
Respiratory Tract ◽  
Disease Burden ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Cost Effective ◽  
Respiratory Viruses ◽  
Global Perspective ◽  
Local Context ◽  
Virological Diagnosis ◽  
Tract Infections

Respiratory viral infections are the leading cause of morbidity and mortality in the world; however, there are several groups of viruses that are insufficiently routinely sought for, and can thus be considered neglected from a diagnostic and clinical standpoint. Timely detection of seasonality of certain respiratory viruses (e.g., enveloped viruses such as seasonal coronaviruses) in the local context can aid substantially in targeted and cost-effective utilization of viral diagnostic approaches. For the other, non-enveloped and year-round viruses (i.e., rhinovirus, adenovirus, and bocavirus), a continuous virological diagnosis needs to be implemented in clinical laboratories to more effectively address the aetiology of respiratory infections, and assess the overall impact of these viruses on disease burden. While the coronavirus disease 2019 (COVID-19) pandemic is still actively unfolding, we aimed to emphasize the persistent role of seasonal coronaviruses, rhinoviruses, adenoviruses and bocaviruses in the aetiology of respiratory infections. Consequently, this paper concentrates on the burden and epidemiological trends of aforementioned viral groups on a global level, but also provides a snapshot of their prevalence patterns in Croatia in order to underscore the potential implications of viral seasonality. An overall global prevalence in respiratory tract infections was found to be between 0.5 and 18.4% for seasonal coronaviruses, between 13 and 59% for rhinoviruses, between 1 and 36% for human adenoviruses, and between 1 and 56.8% for human bocaviruses. A Croatian dataset on patients with respiratory tract infection and younger than 18 years of age has revealed a fairly high prevalence of rhinoviruses (33.4%), with much lower prevalence of adenoviruses (15.6%), seasonal coronaviruses (7.1%), and bocaviruses (5.3%). These insights represent a relevant discussion point in the context of the COVID-19 pandemic where the testing of non-SARS-CoV-2 viruses has been limited in many settings, making the monitoring of disease burden associated with other respiratory viruses rather difficult.

scholarly journals DYNAMICS OF CHILDHOOD RESPIRATORY INFECTIONS DURING THE COVID-19 PANDEMIC: THE EFFECT OF QUARANTINE АND BEYOND

2021 ◽  
Vol 2 (3) ◽  
pp. 153-161
Author(s):  
Snezhina Lazova ◽  
Tsvetelina Velikova
Keyword(s):  
Viral Infections ◽  
Respiratory Infections ◽  
Viral Pathogens ◽  
Positive Effects ◽  
Specific Effects ◽  
Seasonal Characteristics ◽  
Flu Vaccine ◽  
Respiratory Viral Infections ◽  
And Control

Monitoring epidemic processes and the dynamics of the spread of infectious diseases is essential for predicting their distribution and effective planning in healthcare. The importance of studying seasonal trends in the spread of respiratory viral infections and the specific effects of non-pharmaceutical interventions in nationwide scales and the use of available vaccines stand out even more in the context of the coronavirus disease-19 (COVID-19) pandemic. Even if the dynamics of pediatric respiratory viral infections show some variation at the national and local levels, depending on health regulation, respiratory viral pathogens follow a typical pattern of incidence. Therefore, we hypothesize that anticipated reduction of the incidence of common respiratory viral infections would undoubtedly exert positive effects, such as ease of burdening healthcare that combates the COVID-19 pandemic. However, we suspect a shift in familiar seasonal characteristics of common respiratory viral infections. We also speculate that strict long-term limitations of the natural spread of respiratory viral infections can lead to the development of hard-to-predict epidemiological outliers. Additionally, the tricky balance between humanity’s natural impulse to return to normalcy and control the new and still dynamically evolving infection could lead to new threats from old and well-known pathogens. Finally, we hypothesize that the absence of regular influenza virus circulation may lead to a high mismatch rate and a significant reduction in flu vaccine efficacy.

scholarly journals Influenza Prevalence and Vaccine Efficacy in Diabetic Patients in Qatar

2021 ◽  
Author(s):  
Swapna Thomas ◽  
Maria K. Smatti ◽  
Muna A. Al Maslamani ◽  
Hadi Mohamad Yassine
Keyword(s):  
Influenza Virus ◽  
Risk Factor ◽  
Respiratory Tract Infections ◽  
Independent Risk Factor ◽  
Respiratory Infections ◽  
Influenza Infection ◽  
Diabetic Patients ◽  
Test Results ◽  
Flu Vaccination ◽  
Tract Infections

Introduction: Diabetes (DM) is often recognized as ‎an independent risk factor for developing severe respiratory tract infections. Influenza infections are associated with higher hospitalization, morbidity and mortality in DM patients. Vaccination against Influenza virus would reduce the burden of flu infection in DM patients. Aim: To assess the prevalence and burden of influenza infection in DM patients in Qatar and to evaluate the efficacy of influenza vaccination in DM patients Methods: The study included 26,989 patients between 2016- 2018. Virology test results (20 pathogens) as well as the levels of HbA1c were collected for all participant. Data was filtered and analysed to explore the influenza prevalence and vaccine efficiacy among diabetis patients in comparision to non-diabetic. Findings: This study shows that DM patients are at higher-risk for influenza infection. In general, Influenza infections covers around 50 % of total respiratory infections in patients with flu like symptoms in Qatar. However, in vaccinated DM patients, influenza test positivity was low. This study reports the efficacy of routine flu vaccination to reduce the burden of influenza infection in DM patients.

Sign in / Sign up

Export Citation Format

Share Document